Investors' focus will likely be on GILD's HIV franchise performance and oncology sales when the company reports ...

We recently published a list of 10 Best Wide Moat Stocks to Invest In. In this article, we are going to take a look at where ...

Salesforce on Wednesday said former Gilead Sciences finance chief Robin Washington will join the software maker to become ...

Gilead Sciences Inc. hit a new 52-week high, surpassing its previous peak of $99.45, which the company achieved on February ...

Operating Chief Brian Millham to exit after more than 25 at the company. Incoming CFO Robin Washington has served on ...

AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

This was the stock's second consecutive day of losses.

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.